255 related articles for article (PubMed ID: 33871807)
1. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study.
Marafini I; Stolfi C; Troncone E; Lolli E; Onali S; Paoluzi OA; Fantini MC; Biancone L; Calabrese E; Di Grazia A; Monteleone I; Lenti MV; Di Sabatino A; Monteleone G
BioDrugs; 2021 May; 35(3):325-336. PubMed ID: 33871807
[TBL] [Abstract][Full Text] [Related]
2. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
Monteleone G; Di Sabatino A; Ardizzone S; Pallone F; Usiskin K; Zhan X; Rossiter G; Neurath MF
Aliment Pharmacol Ther; 2016 Mar; 43(6):717-24. PubMed ID: 26766141
[TBL] [Abstract][Full Text] [Related]
3. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.
Monteleone G; Neurath MF; Ardizzone S; Di Sabatino A; Fantini MC; Castiglione F; Scribano ML; Armuzzi A; Caprioli F; Sturniolo GC; Rogai F; Vecchi M; Atreya R; Bossa F; Onali S; Fichera M; Corazza GR; Biancone L; Savarino V; Pica R; Orlando A; Pallone F
N Engl J Med; 2015 Mar; 372(12):1104-13. PubMed ID: 25785968
[TBL] [Abstract][Full Text] [Related]
4. CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.
Marafini I; Monteleone I; Dinallo V; Di Fusco D; De Simone V; Laudisi F; Fantini MC; Di Sabatino A; Pallone F; Monteleone G
J Crohns Colitis; 2017 May; 11(5):603-609. PubMed ID: 28453765
[TBL] [Abstract][Full Text] [Related]
5. Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Monteleone G; Stolfi C; Marafini I; Atreya R; Neurath MF
Mol Diagn Ther; 2022 Sep; 26(5):477-481. PubMed ID: 35841457
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease.
Zorzi F; Calabrese E; Monteleone I; Fantini M; Onali S; Biancone L; Pallone F; Monteleone G
Aliment Pharmacol Ther; 2012 Nov; 36(9):850-7. PubMed ID: 22971085
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease.
Monteleone G; Fantini MC; Onali S; Zorzi F; Sancesario G; Bernardini S; Calabrese E; Viti F; Monteleone I; Biancone L; Pallone F
Mol Ther; 2012 Apr; 20(4):870-6. PubMed ID: 22252452
[TBL] [Abstract][Full Text] [Related]
8. Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment.
Arrico L; Stolfi C; Marafini I; Monteleone G; Demartis S; Bellinvia S; Viti F; McNulty M; Cabani I; Falezza A; Di Bari L
Nucleic Acid Ther; 2022 Aug; 32(4):312-320. PubMed ID: 35263186
[TBL] [Abstract][Full Text] [Related]
9. Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.
Feagan BG; Sands BE; Rossiter G; Li X; Usiskin K; Zhan X; Colombel JF
Gastroenterology; 2018 Jan; 154(1):61-64.e6. PubMed ID: 28847751
[TBL] [Abstract][Full Text] [Related]
10. Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases.
Laudisi F; Dinallo V; Di Fusco D; Monteleone G
Curr Drug Metab; 2016; 17(3):303-6. PubMed ID: 26651974
[TBL] [Abstract][Full Text] [Related]
11. Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease.
Ardizzone S; Bevivino G; Monteleone G
Therap Adv Gastroenterol; 2016 Jul; 9(4):527-32. PubMed ID: 27366221
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice.
Izzo R; Bevivino G; De Simone V; Sedda S; Monteleone I; Marafini I; Di Giovangiulio M; Rizzo A; Franzè E; Colantoni A; Ortenzi A; Monteleone G
Inflamm Bowel Dis; 2018 May; 24(6):1213-1224. PubMed ID: 29668937
[TBL] [Abstract][Full Text] [Related]
13. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
Kennedy BW
N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083214
[No Abstract] [Full Text] [Related]
14. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
Monteleone G; Pallone F
N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083213
[No Abstract] [Full Text] [Related]
15. A Novel
Di Fusco D; Marafini I; Stolfi C; Troncone E; Onali S; Lolli E; Caprioli F; Mazza S; Raffaella C; Manzo L; Borgiani P; Giuffrida P; Di Sabatino A; Monteleone I; Monteleone G
Biomedicines; 2020 Jul; 8(8):. PubMed ID: 32707955
[TBL] [Abstract][Full Text] [Related]
16. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
Sands BE; Feagan BG; Sandborn WJ; Schreiber S; Peyrin-Biroulet L; Frédéric Colombel J; Rossiter G; Usiskin K; Ather S; Zhan X; D'Haens G
Am J Gastroenterol; 2020 May; 115(5):738-745. PubMed ID: 31850931
[TBL] [Abstract][Full Text] [Related]
17. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
18. [Good results: antisense-oligonucleotide Mongersen is in Crohn's disease].
Moskaleva M
Dtsch Med Wochenschr; 2015 May; 140(10):710-1. PubMed ID: 26171473
[No Abstract] [Full Text] [Related]
19. Smad7 Antisense Oligonucleotide in Crohn's Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical Trials.
Monteleone G; Stolfi C
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678723
[TBL] [Abstract][Full Text] [Related]
20. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
